Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling
Abstract The cancer genome provides the blueprint for identifying oncogenic mutations driving tumor growth and these mutant proteins and pathways are the targets for precision cancer therapies. However, many oncogenes are capable of reprogramming the landscape of active portion of the genome, common...
Guardado en:
Autores principales: | Feng Liu, Paul S. Mischel, Webster K. Cavenee |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8741ff04de824f7585fff1793dbafe1b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Epigenomics and immunotherapeutic advances in pediatric brain tumors
por: Malak Abedalthagafi, et al.
Publicado: (2021) -
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study
por: Apostolia Maria Tsimberidou, et al.
Publicado: (2021) -
Correction: Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies
Publicado: (2021) -
Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology
por: Frank P. Lin, et al.
Publicado: (2021) -
A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial
por: Istvan Petak, et al.
Publicado: (2021)